Is This Biopharma Company With A Unique Business A Buy?
With a portfolio currently comprised of 45 commercial products and five developmental-stage candidates in various areas, including rare disease and neurology, the company featured in…
Biotech Stocks
“Not All Growth Is Created Equal”: 4 Strong Growth Tech And Biotech Stocks For Aggressive Investors
“With a huge tailwind from the massive stimulus program and the reopening of the economy as spring begins, now is the time to move from…
5 Biotech Stocks To Watch As The Industry Continues To Expand
“The biotech industry seems poised to continue its good run on the back of continued advancements in the field of research and subsequent speeding up…
Will Biotech Buck The Historical Trend This March? (And Where Will Biotech Go After 2021?)
Historically, January and February tend to be very strong months for biotech, while March tends to be very weak. But, with COVID-19 continuing to bear…
Hijacking The Immune System Creates A Huge Opportunity For These Biotech Stocks
A huge opportunity exists for a group of biotech stocks seeking to “hijack the immune system” with bispecific antibodies. Just what are bispecific antibodies –…
5 Health Care Stocks That Could Be Top Performers In 2021
Today’s article highlights five health care stocks that analysts believe could be top performers in 2021, with the author advising that “While certainly not as…
3 Biotech Stocks With Enormous Catalysts Early In 2021
When it comes to stocks with the potential to make big moves in the first quarter of 2021, the author of today’s article advises that…
Top Biotech Picks For 2021 With The Most Upside Potential
In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that…
4 Under-$10 Biotech Stocks With Solid Upside Potential For Aggressive Traders
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher…
3 Biotech Stocks Flying High In The Mid-Cap “Sweet Spot”
In regards to biotech’s bullish year, the author of today’s article notes that “The COVID-19 pandemic has put a fire under many lesser-known names, including…